2021
INNV-07. TTFIELDS TREATMENT OF GLIOSARCOMA AND RECURRENT ANAPLASTIC OLIGODENDROGLIOMA
Blondin N, Fulbright R, Huttner A, Moliterno-Gunel J. INNV-07. TTFIELDS TREATMENT OF GLIOSARCOMA AND RECURRENT ANAPLASTIC OLIGODENDROGLIOMA. Neuro-Oncology 2021, 23: vi106-vi106. DOI: 10.1093/neuonc/noab196.419.Peer-Reviewed Original ResearchYear old womanStable diseaseAnaplastic oligodendrogliomaOlder womenCycles of temozolomideRecurrent anaplastic oligodendrogliomaRecurrent glioblastoma patientsTemporal lobe gliosarcomaTreatment of gliosarcomaGlioma subtypesImproved survival outcomesSmall case seriesStandard of careRight frontal lobeConventional radiation therapyConcurrent temozolomideFurther chemotherapyRadiographic progressionOverall survivalCase seriesInitial diagnosisRadiographic findingsSurvival outcomesSignificant thrombocytopeniaHistorical controls
2016
ACTR-08. BENEFICIAL EFFECT OF TUMOR TREATING FIELD THERAPY IN DIFFUSE ASTROCYTOMA WITH GLIOMATOSIS CEREBRI
Blondin N. ACTR-08. BENEFICIAL EFFECT OF TUMOR TREATING FIELD THERAPY IN DIFFUSE ASTROCYTOMA WITH GLIOMATOSIS CEREBRI. Neuro-Oncology 2016, 18: vi3-vi3. DOI: 10.1093/neuonc/now212.007.Peer-Reviewed Original ResearchSignificant radiographic improvementGliomatosis cerebriRadiographic improvementDiagnostic biopsyCerebral lobesRadiation therapyDiffuse astrocytomasTTFields therapyCombination of TTFieldsCycles of TMZYear old manYear old womanEffective treatment strategiesTumor treating fields therapyTumor Treating FieldsActive diseasePerformance statusRadiographic progressionSurvival benefitAdult astrocytomasNeurological toxicityPatient 1Patient 2Poor prognosisMalignant disease